An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines

Olanow, C. Warren; Watts, Ray L.; Koller, William C.

doi:10.1212/wnl.56.suppl_5.s1

Cited by 715

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines

Olanow, C. Warren, Watts, Ray L., Koller, William C.·2001·Neurology

DOI 10.1212/wnl.56.suppl_5.s1

Open this paper in CoChat — free account

Abstract

Parkinson’s disease (PD) is named in honor of James Parkinson, whose classic monograph, “An Essay on the Shaking Palsy,” written in 1817, has provided an enduring description of the clinical features of this disorder.1 PD is an age-related neurodegenerative disorder with an average age at onset of 60 years. An estimated 1 million persons in the United States suffer from PD,2 and there are approximately 60,000 new cases each year. United States Census Bureau projections indicate that there will be a substantial increase in the number of at-risk individuals 60 years of age and older, and therefore the prevalence of PD is likely to increase in the coming decades. The introduction of levodopa in the late 1960s represented a major therapeutic advance in the management of PD,3 providing clinical benefit to virtually all patients and reduced mortality. However, it soon became apparent that long-term treatment with levodopa is complicated by the development of adverse events that include motor fluctuations, dyskinesias, and neuropsychiatric complications.4-6⇓⇓ In addition, with disease progression, patients develop features that do not respond well to levodopa therapy, such as freezing episodes, autonomic dysfunction, falling, and dementia. As a consequence, despite levodopa treatment, most PD patients eventually suffer disabilities that cannot be satisfactorily controlled with existing medical therapies. Therefore, there has been an intensive effort to develop new treatments that reverse disabilities in patients with advanced disease, that provide enhanced clinical benefits with a reduced risk for adverse events, and that slow the rate of disease progression. This has led to an explosion of new laboratory and clinical information and to a variety of new treatment strategies for the management of PD. Physicians who treat PD patients must now assimilate a considerable body of data to optimally manage patients with this complex disorder. …

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1212/wnl.56.suppl_5.s1

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop*
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Mitochondrial Complex I Deficiency in Parkinson's Disease
Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024

Show all 27 references

Research works printed but not linked: 535

10.1212/WNL.50.1.1 · DOI
10.1056/NEJM196702162760703 · DOI · Paper page
Marsden CD, Parkes JD. “On-off” effects in patients with Parkinson’s disease on chronic levodopa therapy. Lancet . 1976; 1: 292–296.
Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson’s disease. Neurology . 2000; 55 (Suppl 4): S13–S20.
10.1056/NEJM199810083391506 · DOI · Paper page
10.1212/WNL.44.1.1 · DOI · Paper page
Koller WC. How accurately can Parkinson’s disease be diagnosed? Neurology . 1992; 42 (Suppl 1): 6–16.
Koller WC, Montgomery EB. Issues in the early diagnosis of Parkinson’s disease. Neurology . 1997; 49 (Suppl 1): S10–S25.
10.1136/jnnp.55.3.181 · DOI · Paper page
10.1016/S0733-8619(18)30218-4 · DOI
10.1016/S0733-8619(18)30214-7 · DOI
10.1136/jnnp.68.4.434 · DOI · Paper page
10.1212/WNL.48.4.959 · DOI · Paper page
10.1002/1531-8257(200005)15:3<467::AID-MDS1007>3.0.CO;2-# · DOI
10.1002/1531-8257(200005)15:3<474::AID-MDS1008>3.0.CO;2-X · DOI
10.1038/26652 · DOI · Paper page
10.1038/33416 · DOI · Paper page
10.1002/ana.410440612 · DOI · Paper page
10.1093/hmg/8.4.567 · DOI · Paper page
10.1136/jnnp.62.4.305 · DOI
10.1002/1531-8249(199905)45:5<577::AID-ANA5>3.0.CO;2-O · DOI · Paper page
Wood NW. Genetic risk factors in Parkinson’s disease. Ann Neurol . 1998; 44 (Suppl 1): S58–S62.
Horstink MW, Morrish PK. Preclinical diagnosis of Parkinson’s disease. Adv Neurol . 1999; 80: 327–333.
10.1002/ana.410440107 · DOI
10.1002/ana.410410213 · DOI
10.1001/archneur.1990.00530120034007 · DOI · Paper page
Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med . 1998; 39: 1500–1508.
10.1038/jcbfm.1994.99 · DOI · Paper page
Frey KA, Wieland DM, Kilbourn MR. Imaging of monoaminergic and cholinergic vesicular transporters in the brain. Adv Pharmacol . 1998; 42: 269–272.
10.1002/ana.410360512 · DOI · Paper page
10.1002/ana.410340306 · DOI · Paper page
10.1002/ana.410340304 · DOI · Paper page
10.1002/ana.410410111 · DOI · Paper page
10.1146/annurev.neuro.22.1.123 · DOI · Paper page
Golbe LI. The genetics of Parkinson’s disease: a reconsideration. Neurology . 1990; 40 (Suppl 3): 7–14.
10.1002/ana.410360310 · DOI
10.1021/bi961799n · DOI · Paper page
10.1073/pnas.95.11.6469 · DOI · Paper page
10.1016/S0006-8993(00)02215-0 · DOI · Paper page
10.1038/35006074 · DOI · Paper page
10.1056/NEJM200005253422103 · DOI · Paper page
10.1001/jama.281.4.341 · DOI · Paper page
Tanner CM, Langston JW. Do environmental toxins cause Parkinson’s disease? A critical review. Neurology . 1990; 40 (Suppl 3): 17–30.
10.1212/WNL.40.8.1218 · DOI · Paper page
10.1126/science.6823561 · DOI · Paper page
Lin S-K, Chin-Song L, Vingerhoets F, et al. Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observations. Parkinsonism Relat Disord . 1995; 2: 67–72.
10.1038/81834 · DOI · Paper page
10.1212/WNL.45.6.1041 · DOI · Paper page
Jenner P, Olanow CW. Understanding cell death in Parkinson’s disease. Ann Neurol . 1998; 44 (suppl 1): S72–S84.
Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson’s disease. Ann Neurol . 1998; 44 (suppl 1): S142–S148.
10.1002/1531-8257(199903)14:2<383::AID-MDS1037>3.0.CO;2-F · doi:10.1002/1531-8257(199903)14:2<383::aid-mds1037>3.0.co;2-f
10.1016/S0005-2728(98)00167-4 · DOI · Paper page
Olanow CW. Oxidation reactions in Parkinson’s disease. Neurology . 1990; 40 (suppl 3): 32–37.
10.1038/311467a0 · DOI · Paper page
10.1016/0014-2999(84)90700-3 · DOI · Paper page
10.1056/NEJM198911163212004 · DOI · Paper page
10.1056/NEJM199301213280305 · DOI · Paper page
10.1002/ana.410380512 · DOI · Paper page
10.1126/science.2502843 · DOI · Paper page
Olanow CW, Calne D. Does selegiline monotherapy in Parkinson’s disease act by symptomatic or protective mechanisms? Neurology . 1992; 42 (Suppl 4): 13–26.
10.1212/WNL.47.6_Suppl_3.210S · doi:10.1212/wnl.47.6_suppl_3.210s
10.1002/jnr.490300410 · DOI
10.1007/978-1-4615-1857-0_2 · doi:10.1007/978-1-4615-1857-0_2
10.1111/j.1471-4159.1985.tb10556.x · DOI
10.1046/j.1471-4159.1997.68010033.x · DOI
10.1046/j.1471-4159.1997.68010434.x · DOI
Mytilineou C, Leonardi EK, Radcliffe P, et al. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J Pharmacol Exp Ther . 1998; 284: 700–706. · DOI
10.1046/j.1471-4159.1994.63041572.x · doi:10.1046/j.1471-4159.1994.63041572.x
Tatton WG Ju WYH Wadia J Tatton NA. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW Jenner P Youim MHB eds. Neurodegeneration and neuroprotection in Parkinson’s disease. London: Academic Press 1996: 202–220. · DOI
Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol . 2000; 57: 2–12. · DOI · Paper page
10.1074/jbc.273.10.5821 · DOI · Paper page
10.1038/sj.bjp.0703633 · DOI
10.1002/ana.410370117 · doi:10.1002/ana.410370117
10.1002/ana.410390106 · DOI · Paper page
10.1002/ana.410390107 · DOI · Paper page
10.1136/bmj.311.7020.1602 · DOI · Paper page
10.1002/ana.410400605 · DOI
10.1212/WNL.51.3.825 · doi:10.1212/wnl.51.3.825
Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm . 1996; 48 (suppl): 95–101.
10.1002/ana.410440206 · DOI
10.1016/0006-8993(94)90969-5 · DOI · Paper page
10.1002/ana.410440726 · DOI · Paper page
10.1016/0306-4522(96)00249-7 · DOI
10.1016/0014-2999(95)00362-O · DOI · Paper page
10.1002/biof.5520090223 · DOI
10.1038/nm0497-421 · DOI · Paper page
Marsden CD, Olanow CW. The causes of Parkinson’s disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol . 1998; 44 (Suppl 1): S189–S196.
10.1002/1531-8257(200005)15:3<485::AID-MDS1010>3.0.CO;2-F · DOI
Marek KL, Seibyl J, Fussell B, Cellar J, Smith E, Innis R. 123I beta-CIT: assessment of progression in Parkinson’s disease [Abstract]. Neurology . 1997; 48 (Suppl 2): A207–A208.
10.1093/brain/119.2.585 · DOI · Paper page
10.1212/WNL.31.2.125 · doi:10.1212/wnl.31.2.125
10.1212/WNL.39.9.1187 · DOI
10.1016/S0733-8619(18)30213-5 · DOI
10.1017/S0317167100046412 · DOI
10.1212/WNL.34.8.991 · doi:10.1212/wnl.34.8.991
10.1001/archneur.1986.00520040080025 · doi:10.1001/archneur.1986.00520040080025
10.1016/0166-2236(93)90070-3 · DOI · Paper page
Fahn S. Controversies in the therapy of Parkinson’s disease. Adv Neurol . 1996; 69: 477–486.
10.1001/archneur.1995.00540300037010 · DOI
10.1212/WNL.40.10.1529 · DOI · Paper page
10.2165/00002512-199710050-00002 · DOI
10.1002/ana.410390321 · DOI
10.1097/00002826-199106000-00007 · doi:10.1097/00002826-199106000-00007
10.1056/NEJM199309303291408 · DOI · Paper page
10.1212/WNL.43.8.1459 · DOI
10.1212/WNL.47.6_Suppl_3.184S · DOI
10.1016/0022-510X(91)90046-A · DOI
10.1172/JCI117946 · DOI · Paper page
10.1002/mds.870080202 · DOI
10.1016/0304-3940(94)90603-3 · DOI
10.1002/ana.410430504 · DOI · Paper page
10.1212/WNL.31.9.1194 · DOI
10.1002/mds.870010109 · DOI
10.1056/NEJM199504273321702 · DOI · Paper page
10.1002/1531-8257(199911)14:6<911::AID-MDS1001>3.0.CO;2-H · doi:10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h
Koller WC, Hubble JP. Levodopa therapy in Parkinson’s disease. Neurology . 1990; 40 (Suppl 3): 40–47.
10.1016/S1471-1931(00)00031-8 · DOI · Paper page
Muenter MD, Tyce GM. L-dopa therapy of Parkinson’s disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc . 1971; 46: 231–239.
10.1002/ana.410390504 · DOI · Paper page
10.1002/ana.410220415 · DOI · Paper page
10.1002/ana.410240303 · DOI · Paper page
10.1002/ana.410240304 · DOI · Paper page
10.1212/WNL.32.5.514 · DOI · Paper page
10.1002/mds.870080417 · doi:10.1002/mds.870080417
Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia (“I-D-I” and “D-I-D”) in response to 1-dopa therapy for Parkinson’s disease. Mayo Clin Proc . 1977; 52: 163–174.
Barbeau A. High-level levodopa therapy in severely akinetic parkinsonian patients: twelve years later. In: Rinne U Klingler M Stamm B eds. Parkinson’s disease: current progress problems and management. Amsterdam: Elsevier/North-Holland Biomedical Press 1980: 229–239.
Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet . 1977; 1: 345–349.
10.1212/WNL.41.2_Part_1.168 · DOI · Paper page
10.1002/mds.870020201 · DOI · Paper page
10.1093/brain/123.11.2297 · DOI · Paper page
10.1212/WNL.36.11.1528 · DOI · Paper page
10.1159/000117399 · DOI · Paper page
10.1212/WNL.53.5.1012 · DOI · Paper page
Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand . 1996; 93: 14–20.
10.1136/jnnp.57.8.903 · DOI
10.1136/jnnp.57.9.1034 · DOI · Paper page
10.1001/jama.284.15.1931 · DOI · Paper page
10.1016/0166-2236(89)90074-X · DOI · Paper page
10.1016/0166-2236(90)90110-V · DOI · Paper page
10.1523/JNEUROSCI.11-04-01016.1991 · DOI · Paper page
Obeso JA, Rodriguez MC, DeLong MR. Basal ganglia pathophysiology. A critical review. Adv Neurol . 1997; 74: 3–18.
Obeso JA, Rodriguez-Oroz MC, Rodriguez M, DeLong MR, Olanow CW. Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann Neurol . 2000; 47 (Suppl 1): S22–S34.
10.1016/S1471-1931(00)00028-8 · DOI · Paper page
10.1097/00006123-199811000-00001 · DOI · Paper page
10.1002/ana.410440407 · DOI · Paper page
10.1002/ana.410400305 · DOI · Paper page
10.1056/NEJM199710093371503 · DOI · Paper page
10.1056/NEJM199810153391603 · DOI · Paper page
10.1212/WNL.51.3.850 · DOI · Paper page
10.1002/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6 · DOI · Paper page
Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res . 1991; 547: 152–161.
10.1002/ana.410420513 · DOI · Paper page
Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol . 2000; 47 (Suppl 1): S167–S176.
10.1002/ana.410250521 · doi:10.1002/ana.410250521
10.1002/ana.410360108 · DOI · Paper page
10.1212/WNL.48.2.369 · DOI
10.1016/0006-8993(94)90796-X · DOI · Paper page
10.1523/JNEUROSCI.04-11-02866.1984 · DOI · Paper page
Schultz W. Behavior-related activity of primate dopamine neurons. Rev Neurol . 1994; 150: 634–639.
10.1002/ana.410250509 · DOI · Paper page
10.1016/0006-8993(86)90783-3 · DOI · Paper page
10.1002/mds.870130207 · DOI · Paper page
10.1016/0014-4886(92)90125-A · DOI
Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther . 1995; 272: 854–859. · DOI
10.1016/S1471-1931(00)00025-2 · DOI
Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol . 2000; 47 (Suppl 1): S70–S78.
10.1016/S0169-328X(97)00123-X · DOI
Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res . 1991; 547: 152–161.
Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson’s disease. Neurology . 1989; 39 (Suppl 2): 7–10.
Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Drugs . 1998; 55 (Suppl 1): 1–9.
10.1016/S1471-1931(00)00030-6 · DOI · Paper page
10.1017/S0317167100041469 · DOI
Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson’s disease: a review. J Neural Transm . 1995; 45 (Suppl): 187–195.
Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson’s disease. Drugs . 1996; 5: 369–388.
10.1017/S0317167100046448 · doi:10.1017/s0317167100046448
10.1056/NEJM198402233100802 · DOI · Paper page
10.1016/0091-3057(91)90603-Y · DOI
Kartzinel R, Teychenne P, Gillespie MM, et al. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet . 1976; 2: 272–275.
10.1056/NEJM197612162952504 · doi:10.1056/nejm197612162952504
10.1212/WNL.35.2.199 · doi:10.1212/wnl.35.2.199
10.1002/mds.870090107 · DOI · Paper page
10.1159/000115567 · DOI
10.1212/WNL.43.3_Part_1.613 · doi:10.1212/wnl.43.3_part_1.613
10.1212/WNL.49.1.162 · DOI · Paper page
10.1212/WNL.49.4.1060 · DOI · Paper page
10.1212/WNL.51.4.1057 · DOI · Paper page
10.1097/00002826-199619030-00005 · doi:10.1097/00002826-199619030-00005
Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet . 1988; 1: 403–406.
10.1002/mds.870080208 · DOI · Paper page
10.1002/mds.870110319 · doi:10.1002/mds.870110319
10.1016/S1471-1931(00)00029-X · DOI
10.1093/brain/114.1.601 · doi:10.1093/brain/114.1.601
10.1002/mds.870100108 · doi:10.1002/mds.870100108
10.1136/jnnp.64.5.573 · DOI · Paper page
10.1136/jnnp.65.5.709 · DOI · Paper page
10.1002/1531-8249(200001)47:1<122::AID-ANA21>3.0.CO;2-9 · DOI
Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther . 1993; 267: 275–279. · doi:10.1016/s0022-3565(25)39350-x
10.1212/WNL.37.5.826 · DOI
10.1212/WNL.43.1_Part_1.21 · DOI
10.1001/jama.1997.03550020057038 · DOI

200 of 535 shown

A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
Olanow, C. W., Goetz, C. G., Kordower, J. H., Stoessl, A. J., Sossi, V., Brin, M. F., Shannon, K. M., Nauert, G. M., Perl, D. P., Godbold, J., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10720 · Cited by 1,307
Self-citation
Association of dopamine agonist use with impulse control disorders in Parkinson disease
Weintraub, D., Siderowf, A. D., Potenza, M. N., Goveas, J., Morales, K. H., Duda, J. E., Moberg, P. J., & Stern, M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.7.969 · Cited by 662
ESPEN guideline clinical nutrition in neurology
Burgos, R., Bretón, I., Cereda, E., Desport, J. C., Dziewas, R., Genton, L., Gomes, F., Jésus, P., Leischker, A., Muscaritoli, M., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.09.003 · Cited by 571
The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson’s disease11No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit upon the authors(s) or upon any organization with which the author(s) is/are associated.
Hirsch, M. A., Toole, T., Maitland, C. G., & Rider, R. A. (2003) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(03)00046-7 · Cited by 455
Machine Learning and Deep Learning in smart manufacturing: The Smart Grid paradigm
Kotsiopoulos, T., Sarigiannidis, P., Ioannidis, D., & Tzovaras, D. (2021) · Computer Science Review · doi:10.1016/j.cosrev.2020.100341 · Cited by 341

See all 715

Authors: Olanow, C. W., Watts, R. L., & Koller, W. C.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2001-06-12
Volume: 56
Issue: suppl_5
Pages: 156; author reply 156-7
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.56.suppl_5.s1
OpenAlex: W2103964804
Cited by: 715
References: 27
FWCI: 32.73
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page: CoChat. (2026). Citation check: An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines. https://app.cochat.ai/papers/10.1212/wnl.56.suppl_5.s1
The paper: Olanow, C. W., Watts, R. L., & Koller, W. C. (2001). An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines. Neurology. https://doi.org/10.1212/wnl.56.suppl_5.s1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

An algorithm (decision tree) for the management of Parkinson’s disease (2001): Treatment Guidelines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

How to cite

Data sources